TNF and neoplasm: Since systemic administration of potent immunostimulatory factors, such as type I Interferons, tumor necrosis factor alpha (TNFα), or interleukin 12 (IL-12), may have considerable side effects, delivery by oAds provides an attractive option to focus cytokine activity on the target tumor.